Redeye notes that Sedana Medical’s Q4 report showed higher sales than our estimates, though EBITDA w...
Redeye reinforces its positive view of Vertiseit following its Q4 report.
ExpreS2ion Biotechnologies inriktar resurserna på att ansöka om godkännande för att inleda en fas 1-...
After several commercial contracts signed in 2023, Agtira ended the year with a strong cash position...
Sales -3% vs. ABGSCe, adj. EBIT -28% vs. ABGSCe Drop in utilisation lowered sales by ~8% y-o-y alone...
Sprint Bioscience recorded sales improved to SEK 10.
Redeye provides an update in relation to SenzaGen’s H2 2023 report.
Taaleri's Q4 results were well in line with LSEG Data & Analytics consensus, while the dividend prop...
Redeye comments on Thunderful Group’s preliminary Q4 numbers, which are significantly lower than our...
Media still shining, with 24% org. sales and 19% FTD growth Platform & Sportsbook pipeline doubled s...
Redeye’s expectations for the fourth quarter were basically in-line with reported numbers.
Redeye comments on Ultimovacs’ Q4 2023 report, with the company having confirmed its intention to co...
Redeye provides its comment on Mendus’ Q4 2023 report.
CirChem har publicerat bolagets delårsrapport för det fjärde kvartalet 2023 och rapporterar det bäst...
Finnair’s Q4 results came in much as estimated, although slightly below estimates.
Redeye provides a brief comment on Sprint Bioscience’s Q4 report.
Redeye comments on Safeture's Q4 2023 report, which was considerably stronger than our estimate on t...
Redeye comments on GiG’s Q4-results where revenue was slightly higher than expected while EBITDA was...
Taaleri reported Q4 EBIT of EUR 6.9m, coming well in line with LSEG Data & Analytics consensus at EU...
Moderating growth rebound expectations for Algo '23e-'25e sales down 7-1% '24e EV/EBITDA of 7x What...
.jpg)
